AZD-5069

Generic Name: AZD-5069

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₂F_₂N_₄O_₅S_₂

CAS Number: 878385-84-3

Unique Ingredient Identifier: 4ADT8JXB9S

Clinical Trials

Combination Study of AZD5069 and Enzalutamide.

Phase 1

Terminated

Conditions: Metastatic Castration Resistant Prostate Cancer

Interventions: Drug: AZD5069
Drug: Enzalutamide 40 MG

First Posted Date: 2017-06-06

Last Posted Date: 2023-07-13

Lead Sponsor: Institute of Cancer Research, United Kingdom

Target Recruit Count: 30

Registration Number: NCT03177187

Locations: 🇨🇭
Bellinzona Hospital, Bellinzona, Switzerland
🇬🇧
University Hospital Southampton, Southampton, United Kingdom
🇬🇧
Belfast City Hospital, Belfast, UK, United Kingdom

and more 1 locations

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: AZD9150
Drug: MEDI4736
Drug: AZD5069
Drug: tremelimumab (treme)

First Posted Date: 2015-07-16

Last Posted Date: 2025-04-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 340

Registration Number: NCT02499328

Locations: 🇬🇧
Research Site, Taunton, United Kingdom

Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD).

Interventions: Drug: AZD4721
Drug: Placebo
Drug: AZD5069

First Posted Date: 2013-10-16

Last Posted Date: 2015-06-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 84

Registration Number: NCT01962935

Locations: 🇬🇧
Research Site, London, United Kingdom

Distribution of Neutrophils in Bronchial Mucosal Tissue in Asthma Patients Before and After 4 Weeks Treatment With AZD 5069

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: AZD5069

First Posted Date: 2013-07-01

Last Posted Date: 2016-02-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 13

Registration Number: NCT01890148

Locations: 🇩🇪
Research Site, Grosshansdorf, Germany

Phase I Study to Assess the Effect on Healthy Male Volunteers of Ketoconazole on the Pharmacokinetics of a Single Dose of AZD5069 Administered Orally.

Phase 1

Completed

Conditions: Asthma,
Pharmacokinetics,
λz,
Metabolite
Cmax,
Ketoconazole,
AUC,
Tmax,

Interventions: Drug: AZD5069
Drug: Ketoconazole

First Posted Date: 2012-11-28

Last Posted Date: 2015-06-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 15

Registration Number: NCT01735240

A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma.

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: AZD5069

First Posted Date: 2012-10-11

Last Posted Date: 2016-03-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 1147

Registration Number: NCT01704495

Locations: 🇬🇧
Research Site, London, United Kingdom

Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis

Phase 2

Completed

Conditions: Bronchiectasis
Lung Disease
Respiratory Diseases

Interventions: Drug: Placebo
Drug: AZD5069

First Posted Date: 2010-12-07

Last Posted Date: 2015-10-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 83

Registration Number: NCT01255592

Locations: 🇬🇧
Research Site, Wolverhampton, United Kingdom

Japanese Single and Multiple Ascending Dose (JSMAD), Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of AZD5069

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: AZD5069
Drug: Placebo

First Posted Date: 2010-04-08

Last Posted Date: 2015-06-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 63

Registration Number: NCT01100047

Locations: 🇬🇧
Research Site, Croydon, United Kingdom

This Study Will Investigate How Food and Age Effect the Way the Body Handles the AZD5069 Drug Given as a Oral Dose

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: AZD5069

First Posted Date: 2010-03-09

Last Posted Date: 2015-06-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 24

Registration Number: NCT01083238

Locations: 🇬🇧
Research Site, London, United Kingdom

A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Ascending Doses of AZD5069 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: AZD5069
Drug: Placebo

First Posted Date: 2010-01-18

Last Posted Date: 2015-06-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 8

Registration Number: NCT01051505

Locations: 🇬🇧
Research Site, London Bridge, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy